Core Viewpoint - The stock of Zymeworks Inc. (02617) has experienced a decline of over 10%, currently trading at 84.7 HKD, with a transaction volume of 117 million HKD [1] Group 1: Stock Performance - Zymeworks Inc. shares fell by 9.02% to 84.7 HKD as of the latest report [1] - The stock has seen a significant drop following the announcement of a new share placement [1] Group 2: Share Placement Announcement - The company plans to place 21 million new shares at a price of 92.85 HKD per share, representing a discount of 17.98% compared to the closing price of 113.2 HKD on January 13 [1] - The net proceeds from the placement are expected to be 190 million HKD [1] Group 3: Use of Proceeds - Approximately 60% of the funds will be allocated to clinical trials for the core product Tinengotinib in treating cholangiocarcinoma (CCA) and other indications [1] - About 30% of the proceeds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% will be utilized for working capital and general corporate purposes [1]
港股异动 | 药捷安康-B(02617)再跌超10% 拟配股净筹1.9亿港元 主要用于核心产品研发